An Open-label, Randomized, 4-period, 4-treatment, Cross-over, Single-center, Single-dose Study to Assess the Relative Bioavailability of Ticagrelor in Different Formulations in Healthy Adult Subjects

Trial Profile

An Open-label, Randomized, 4-period, 4-treatment, Cross-over, Single-center, Single-dose Study to Assess the Relative Bioavailability of Ticagrelor in Different Formulations in Healthy Adult Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 04 Aug 2017

At a glance

  • Drugs Ticagrelor (Primary)
  • Indications Abdominal aortic aneurysm; Acute coronary syndromes; Cardiovascular disorders; Community-acquired pneumonia; Coronary artery disease; Sickle cell anaemia; Stroke
  • Focus Pharmacokinetics
  • Sponsors AstraZeneca
  • Most Recent Events

    • 01 Aug 2017 Status changed from active, no longer recruiting to completed.
    • 20 Jun 2017 Planned End Date changed from 3 Jul 2017 to 11 Jul 2017.
    • 20 Jun 2017 Planned primary completion date changed from 3 Jul 2017 to 11 Jul 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top